TY - JOUR
T1 - Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1
T2 - Results of the TARGET study
AU - Henry, Keith
AU - Wallace, Robert J.
AU - Bellman, Paul C.
AU - Norris, Dorece
AU - Fisher, Robin L.
AU - Ross, Lisa L.
AU - Liao, Qiming
AU - Shaefer, Mark S.
PY - 2001/2/15
Y1 - 2001/2/15
N2 - This open-label, multicenter, single-arm clinical trial assessed the 48-week efficacy of a twice-daily triple nucleoside reverse-transcriptase inhibitor regimen containing a lamivudine (150 mg)-zidovudine (300 mg) combination tablet (COM) and abacavir (ABC; 300 mg) in 87 antiretroviral therapy-experienced, protease inhibitor-naive patients infected with human immunodeficiency virus type 1 (HIV-1). At baseline, the median plasma HIV-1 RNA level was 3.10 log10 copies/mL, and the median CD4 cell count was 506 cells/mm3. An intent-to-treat: observed analysis showed that, at weeks 24 and 48 of treatment, HIV-1 RNA level was <400 copies/mL in 48 (76%) of 63 and 45 (82%) of 55 patients, respectively, and <50 copies/mL in 37 (59%) of 63 and 31 (56%) of 55 patients, respectively. Previous zidovudine or lamivudine use and presence at baseline of the M184V reverse-transcriptase mutation did not impact virologic response. Median CD4 cell counts were maintained above baseline throughout the study. COM plus ABC was generally well tolerated.
AB - This open-label, multicenter, single-arm clinical trial assessed the 48-week efficacy of a twice-daily triple nucleoside reverse-transcriptase inhibitor regimen containing a lamivudine (150 mg)-zidovudine (300 mg) combination tablet (COM) and abacavir (ABC; 300 mg) in 87 antiretroviral therapy-experienced, protease inhibitor-naive patients infected with human immunodeficiency virus type 1 (HIV-1). At baseline, the median plasma HIV-1 RNA level was 3.10 log10 copies/mL, and the median CD4 cell count was 506 cells/mm3. An intent-to-treat: observed analysis showed that, at weeks 24 and 48 of treatment, HIV-1 RNA level was <400 copies/mL in 48 (76%) of 63 and 45 (82%) of 55 patients, respectively, and <50 copies/mL in 37 (59%) of 63 and 31 (56%) of 55 patients, respectively. Previous zidovudine or lamivudine use and presence at baseline of the M184V reverse-transcriptase mutation did not impact virologic response. Median CD4 cell counts were maintained above baseline throughout the study. COM plus ABC was generally well tolerated.
UR - http://www.scopus.com/inward/record.url?scp=0035865875&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035865875&partnerID=8YFLogxK
U2 - 10.1086/318527
DO - 10.1086/318527
M3 - Article
C2 - 11170982
AN - SCOPUS:0035865875
SN - 0022-1899
VL - 183
SP - 571
EP - 578
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 4
ER -